In the TROPHIMMUN trial, conducted by You et al., the anti-PD-L1 antibody avelumab achieved a response in 53 % of patients with methotrexate-resistant low-risk GTN (You et al., 2020, You et al., 2023). The gene discussed is CD274; the disease is gestational trophoblastic neoplasm.